A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Clinical trial NCT07136077 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07136077
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Minimal Residual Disease Adjuvant Chemotherapy Colorectal Cancer Fruquintinib Tislelizumab ctDNA

Start date: 2025-09-18
Primary completion: 2027-12-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.